Physician profile

Sara Beeler

Oncology (Clinical Nurse Specialist) · Tampa, FL

NPI 1720328198

$337,477.83

in general payments reported to CMS, 2019-2025

75 companies · $61K in 2025

The $61K reported for 2025 was more than what 99% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$176,400.00
Food and Beverage$21,316.43
Travel and Lodging$18,133.14
Consulting Fee$6,880.00
Long Term Medical Supply Or Device Loan$882.41
Education$110.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $266,212.58 2021-2025 Lynparza, Enhertu, Imfinzi
Daiichi Sankyo INC. $54,568.03 2021-2025 Enhertu, Datroway
Novartis Pharmaceuticals Corporation $2,653.63 2022-2025 Piqray, Kisqali
Janssen Biotech, INC. $1,076.92 2021-2025 Erleada, Rybrevant, Darzalex
E.R. Squibb & Sons, L.L.C. $1,038.61 2021-2025 Opdivo, Opdualag, Eliquis
Gilead Sciences, INC. $931.24 2022-2025 Trodelvy
Celgene Corporation $896.19 2022-2025 Reblozyl, Pomalyst, Breyanzi
Pfizer INC. $796.97 2022-2025
Incyte Corporation $684.34 2021-2025 Jakafi, Monjuvi, Zynyz
Merck Sharp & Dohme LLC $664.35 2021-2025 Keytruda, Lynparza, Welireg
Lilly USA, LLC $495.49 2021-2025 Verzenio, Jaypirca, Retevmo
Abbvie INC. $468.74 2021-2025
Eisai INC. $367.41 2021-2025
Glaxosmithkline, LLC. $352.94 2021-2025 Ojjaara, Zejula, Jemperli
Regeneron Healthcare Solutions, INC. $345.70 2022-2025 Libtayo
Show all 75 companies
CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $331.06 2021-2025 Vyloy, Xospata, Padcev
Puma Biotechnology, INC. $315.64 2021-2025
Seagen INC. $296.20 2021-2023 Tukysa, Padcev, Tivdak
Bayer Healthcare Pharmaceuticals INC. $294.42 2021-2025
Genzyme Corporation $277.29 2021-2025
Amgen INC. $276.88 2021-2023 Vectibix, Nplate, Xgeva
Takeda Pharmaceuticals U.S.A., INC. $272.52 2023-2025 Fruzaqla, Alunbrig, Hyqvia
Tersera Therapeutics LLC $249.23 2024-2025 Zoladex
Pharmacyclics LLC, An Abbvie Company $236.70 2021-2023 Imbruvica, Epkinly
Kite Pharma, INC. $199.15 2022-2025 Yescarta
Beigene USA, INC. $151.61 2023-2024 Brukinsa, Tevimbra
Exelixis INC. $147.39 2021-2025 Cabometyx
Deciphera Pharmaceuticals INC. $145.92 2021-2025 Qinlock, Romvimza
Sumitomo Pharma America, INC. $136.44 2023-2025 Orgovyx
Stemline Therapeutics INC. $129.19 2023-2025 Orserdu
Dendreon Pharmaceuticals LLC $129.03 2023-2025 Provenge
Taiho Oncology, INC. $118.37 2022-2025
Pharmaessentia USA Corporation $118.20 2023-2025 Besremi
Rigel Pharmaceuticals, INC. $113.01 2023-2025 Rezlidhia, Tavalisse, Gavreto
Legend Biotech USA INC. $111.43 2024-2025 Carvykti
Karyopharm Therapeutics INC. $108.41 2022-2025 Xpovio
Genentech USA, INC. $103.81 2022-2025 Tecentriq, Polivy, Alecensa
Pharmacosmos Therapeutics INC. $98.08 2023-2025 Monoferric, Cosela
Aveo Pharmaceuticals, INC. $97.77 2022-2025 Fotivda
Mirati Therapeutics, INC. $92.35 2023-2024 Krazati
Emd Serono, INC. $87.53 2022-2025 Bavencio
Genmab U.S., INC. $85.35 2024-2025 Epkinly
Sobi, INC $78.58 2022-2025
Ipsen Biopharmaceuticals, INC $77.51 2022-2024 Onivyde, Somatuline Depot
Jazz Pharmaceuticals INC. $76.00 2023-2025
Blueprint Medicines Corporation $66.80 2021-2025 Ayvakit
Boston Scientific Corporation $64.71 2022-2024 Wavewriter Alpha Prime 16
Geron Corporation $63.33 2024-2025 Rytelo
Array Biopharma INC $59.38 2023-2025 Braftovi, Mektovi, Tukysa
Myriad Genetic Laboratories, INC. $51.69 2024 Myrisk
Cti Biopharma Corp. $42.48 2023 Vonjo
Agios Pharmaceuticals, INC. $38.36 2023-2025 Pyrukynd
Ge Healthcare $36.38 2022
G1 Therapeutics, INC. $36.34 2022-2023 Cosela
Csl Behring $36.28 2022-2023 Afstyla, Idelvion
Alexion Pharmaceuticals, INC. $33.73 2024-2025 Ultomiris
Adc Therapeutics America, INC. $33.49 2025
Myovant Sciences INC. $31.65 2022
Recordati_rare_diseases_inc. $30.22 2023-2024 Sylvant
Immunocore Limited $29.24 2025 Kimmtrak
Boehringer Ingelheim Pharmaceuticals, INC. $29.22 2022
Tg Therapeutics, INC. $28.89 2022
Kyowa Kirin, INC. $28.58 2022-2024 Poteligeo
Springworks Therapeutics, INC. $27.74 2024 Ogsiveo
Sun Pharmaceutical Industries INC. $25.86 2024
Telix Pharmaceuticals $24.57 2023 Illuccix
Syndax Pharmaceuticals, INC. $21.86 2025
Alnylam Pharmaceuticals INC. $21.37 2022
Heron Therapeutics, INC. $21.32 2022
Morphosys, US INC. $16.04 2023 Monjuvi
Foundation Medicine, INC. $14.52 2023
Shield Therapeutics INC $14.21 2024
Beone Medicines USA, INC. $14.11 2025 Brukinsa
Acrotech Biopharma INC. $13.72 2022
Global Blood Therapeutics, INC. $13.53 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sara Beeler

$337,477.83

in general payments reported 2019-2025

Years
2021-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $61K reported for 2025 was more than what 99% of Oncology (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $263).

https://glasscript.com/doctor/10541308/sara-beeler

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.